Literature DB >> 24656139

Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes.

S Calanna1, R Scicali1, A Di Pino1, F K Knop2, S Piro1, A M Rabuazzo1, F Purrello3.   

Abstract

BACKGROUND AND AIMS: We aimed to investigate lipid abnormalities and liver steatosis in patients with HbA1c-defined prediabetes and type 2 diabetes compared to individuals with HbA1c-defined normoglycaemia. METHODS AND
RESULTS: Ninety-one subjects with prediabetes according to HbA1c, i.e. from 5.7 to 6.4% (39-46 mmol/mol), 50 newly diagnosed patients with HbA1c-defined type 2 diabetes (HbA1c ≥6.5% [≥48 mmol/mol]), and 67 controls with HbA1c lower than 5.7% (<39 mmol/mol), were studied. Fasting blood samples for lipid profiles, fatty liver index (FLI), bioimpedance analysis, ultrasound scan of the liver, and BARD (body mass index, aspartate aminotransferase/alanine aminotransferase ratio, diabetes) score for evaluation of liver fibrosis, were performed in all subjects. In comparison to controls, subjects with prediabetes were characterised by: lower apolipoprotein AI and HDL cholesterol levels, higher blood pressure, triglycerides levels and apolipoprotein B/apolipoprotein AI ratio, higher FLI, increased prevalence of and more severe hepatic steatosis, similar BARD score, and higher total body fat mass. In comparison to subjects with diabetes, subjects with prediabetes exhibited: similar blood pressure and apolipoprotein B/apolipoprotein AI ratio, similar FLI, reduced prevalence of and less severe hepatic steatosis, lower BARD score, increased percent fat and lower total body muscle mass. In comparison to controls, subjects with diabetes showed: lower apolipoprotein AI and HDL cholesterol levels, higher blood pressure and triglycerides levels, higher FLI, increased prevalence of and more severe hepatic steatosis, higher BARD score, and higher total body muscle mass. Moreover, HbA1c was correlated with BMI, HOMA-IR, triglycerides, HDL cholesterol, AST, and ALT.
CONCLUSIONS: Subjects with HbA1c-defined prediabetes and type 2 diabetes, respectively, are characterised by abnormalities in lipid profile and liver steatosis, thus exhibiting a severe risk profile for cardiovascular and liver diseases.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apolipoprotein; Cardiovascular risk; Liver steatosis; Prediabetes; Type 2 diabetes

Mesh:

Substances:

Year:  2014        PMID: 24656139     DOI: 10.1016/j.numecd.2014.01.013

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  7 in total

1.  Disease-specific plasma levels of mitokines FGF21, GDF15, and Humanin in type II diabetes and Alzheimer's disease in comparison with healthy aging.

Authors:  Maria Conte; Jacopo Sabbatinelli; Antonio Chiariello; Morena Martucci; Aurelia Santoro; Daniela Monti; Marina Arcaro; Daniela Galimberti; Elio Scarpini; Anna Rita Bonfigli; Angelica Giuliani; Fabiola Olivieri; Claudio Franceschi; Stefano Salvioli
Journal:  Geroscience       Date:  2020-10-31       Impact factor: 7.713

Review 2.  Update on pre-diabetes: Focus on diagnostic criteria and cardiovascular risk.

Authors:  Antonino Di Pino; Francesca Urbano; Salvatore Piro; Francesco Purrello; Agata Maria Rabuazzo
Journal:  World J Diabetes       Date:  2016-10-15

3.  Effects of curcumin on glycemic control and lipid profile in prediabetes and type 2 diabetes mellitus: A systematic review and meta-analysis.

Authors:  Nalinee Poolsup; Naeti Suksomboon; Putu Dian Marani Kurnianta; Kulchalee Deawjaroen
Journal:  PLoS One       Date:  2019-04-23       Impact factor: 3.240

4.  Obesity and Prediabetes are Jointly Associated with Lipid Abnormalities Among Adolescents: A Cross-Sectional Study.

Authors:  Mohammad Almari; Anwar Mohammad; Jehad Abubaker; Ali H Ziyab
Journal:  Diabetes Metab Syndr Obes       Date:  2021-01-22       Impact factor: 3.168

5.  Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease.

Authors:  A Reum Choe; Dong-Ryeol Ryu; Hwi Young Kim; Hye Ah Lee; Jiyoung Lim; Jin Sil Kim; Jeong Kyong Lee; Tae Hun Kim; Kwon Yoo
Journal:  BMC Nephrol       Date:  2020-02-17       Impact factor: 2.388

6.  Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation.

Authors:  Roberto Scicali; Antonino Di Pino; Chiara Pavanello; Alice Ossoli; Arianna Strazzella; Antonia Alberti; Stefania Di Mauro; Alessandra Scamporrino; Francesca Urbano; Agnese Filippello; Salvatore Piro; Agata Maria Rabuazzo; Laura Calabresi; Francesco Purrello
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

7.  Lotus Seedpod Extracts Reduced Lipid Accumulation and Lipotoxicity in Hepatocytes.

Authors:  Yen-Tze Liu; Yen-Hsun Lai; Hui-Hsuan Lin; Jing-Hsien Chen
Journal:  Nutrients       Date:  2019-11-28       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.